The company is beginning to confirm an number of speaking engagements late July / early September
http://www.i-newswire.com/pr177289.html
http://www.ibclifesciences.com/beyond/overview.xml
They are indicating that results from the CD40/CD40L ligand work will be presented. (Rheumatoid Arthritis - RA - therapy).
The speaking engagements confirmed by the company, on the web site, are late September and beyond.
We are mixing with GSK-Domantis, Adnexus (BMS owned) <- exactly the right company to pique pharma interest in our technology and drug leads.
I am expecting early September as the time we understand the full scope of the recent company developments (and successes) in the RA programme.
company presentations
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $461.9M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.8¢ | $398.0K | 3.957M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 153489 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 127842 | 2 |
View Market Depth
| Last trade - 14.24pm 29/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |